tbuckley/cabot-search huggingface dataset:
Abstract 16678: Multigenic Etiology of CHD With Heterotaxy Involving PCD and Cilia Genes
Authors: You Li, Hisato Yagi, Ewenza O Onuoha, Michael Barmada, Michael Tsang, Cecilia Lo
Journal: Circulation (2011)

Introduction: We recently showed patients with CHD associated with heterotaxy can exhibit respiratory ciliary dysfunction (CD) similar to that of patients with primary ciliary dyskinesia (PCD) - a ciliopathy with airway mucociliary clearance defects. As both PCD and heterotaxy have a 1 in 10,000 incidence, the finding of CD in heterotaxy patients likely reflects the dual role of motile cilia in airway clearance and left-right patterning. Thus, we hypothesize heterotaxy may arise from mutations in PCD genes and other cilia related ciliome genes. Methods and Results: CHD patients with heterotaxy, 13 with CD and 13 without CD (no-CD), were sequence captured followed by SOLiD sequencing at 40X coverage to identify sequence variants in all 13 PCD genes and nearly 1000 other ciliome genes. Coding variants were filtered against dbSNP and the 1000 Genomes databases, and novel coding variants (NCV) were validated by Sanger sequencing. Analysis of the 13 PCD genes revealed 10 NCV in 7 CD patients, and 5 NCV in 3 no-CD patients. The 3 PCD patients had 5 NCV, with 2 siblings having homozygous CCDC39 mutation (1072delA) known to cause PCD. Interestingly, CD-heterotaxy patient 9002 was heterozygous for the most common pathogenic DNAI1 mutation, IVS1+2_3insT, a disease NCV not seen in the general population. As PCD is a recessive disorder, we evaluated NCVs found in DNAH6 , a motor dynein gene not yet demonstrated to cause PCD. DNAH6 NCVs were found in 9002 and one other CD and one PCD patient, but not in any no-CD patient. Dnah6 morpholino (MO) knockdown (KD) in zebrafish embryos showed laterality defects and phenotypes consistent with heterotaxy, suggesting a role in CD and heterotaxy. Conclusion: Our study showed heterotaxy patients with CD can have heterozygous NCVs in PCD genes, including known disease causing DNAI1 mutation. Functional analysis with zebrafish MO showed DNAH6 KD can cause heterotaxy. We propose DNAH6/DNAI1 double heterozygous mutation may contribute to CD and heterotaxy.
真是“急性胃肠炎”吗？
Authors: 金世红
Journal: BMJ (2007)

我在医院急诊科值班时通常情况下都比较忙，常常是一个病人还没处理完，下一个病人又来了，原则上当然是优先处理危重病人。不过我也有过忙中出错的情况。有一次值夜班时来了一位女病人，32岁，诉说自己晚上吃了几个桃子，2小时后就出现“拉肚子”，排稀水样便，没有脓血。伴有呕吐及轻微下腹痛。那时急诊室里已经有好几个病人在等我去处理，我正忙得不可开交，一听是“腹泻”，就让护士把她直接带去医院专设的肠道门诊。等忙过一阵，处理好手上的几个病人后，我又想起刚才去肠道门诊的那个女病人，觉得她的面色似乎有点苍白——她真是“急性胃肠炎”吗？我隐隐地感觉有点不放心，就直接跑到肠道门诊去问问情况，才知道这个病人已被紧急送到妇科手术室做手术去了。
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.
Authors: S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S. Higano, M. E. Gleave, K. N. Chi
Journal: Journal of Clinical Oncology (2010)

3077 Background: Hsp27 is a chaperone protein that affects multiple pathways implicated in cancer progression and treatment resistance. OGX-427 is a 2nd generation ASO that inhibits Hsp27 expression resulting in cell growth inhibition, apoptosis, and enhanced chemotherapy efficacy. The purpose of this study was to determine the safety profile and Phase 2 dose of OGX-427 alone and in combination with docetaxel (D). Methods: Eligible patients (pts) had metastatic castrate resistant prostate cancer (CRPC), breast, non-small cell lung (NSCLC), or ovarian cancer. OGX-427 was administered IV weekly on a 21-day schedule after 3 loading doses. OGX-427 was escalated over 5 planned dose levels (DL) (200-1,000 mg) and OGX-427+D (75mg/m2) over 2 DL (800 and 1,000 mg) with 6 pts/DL. Results: 36 pts were treated with OGX-427 and 12 with OGX-427+D. Median age was 62 (33-86) yrs ; 27 pts had CRPC, 11 breast, 5 ovary and 5 NSCLC ; median prior chemotherapy regimens was 3 (0-6). 1 pt had dose-limiting toxicity with a grade 3 cerebral bleed into a metastasis. Of 556 infusions, 1 dose needed modification for toxicity. Infusion reactions (rigors, pruritus, flushing, back pain, dyspnea) were seen at DL ≥600 mg (interruption 14 pts, discontinuation 5 pts). PTT transiently increased to ≥ twice pretherapy levels at Cmax in 71% pts at DL≥ 800mg. The most common serious adverse events were dyspnea (5) and hydronephrosis/high creatinine (2). In pts with measurable disease, 4/30 given OGX-427 had a confirmed minor response or stable disease (SD) as best response and, of 7 pts with CRPC given OGX-427+D, 2 had a partial response and 1 SD for 7 months. PSA declines of ≥30% were seen in 3/16 (OGX-427) and 5/9 (OGX-427+D) evaluable pts. Of 41 pts with total or Hsp27+ circulating tumor cell (CTC) counts >5 at baseline, 10/32 (OGX-427) and 5/9 (OGX-427+D) pts decreased to ≤5. Conclusions: OGX-427 at the maximum doses tested of 1,000 mg was well tolerated and combination with D was feasible. Toxicity consisted mainly of infusion reactions and transient PTT changes. Changes in tumor markers, measurable disease, and CTC suggested single-agent activity. Further study of OGX-427 alone and in combination with D is planned. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Oncogenex Technologies Oncogenex Technologies Oncogenex Technologies
Abstract 21305: Sustained Sildenafil Treatment Improves Left Ventricular Function and Attenuates Adverse Remodeling One Year After Myocardial Infarction in Mice.
Authors: Peter Pokreisz, Sara Vandenwijngaert, Arpad Lux, Peter Liu, Marijke Pellens, Hilde Gillijns, Ellen Caluwe, Nina Vanden Driessche, Paul Veulemans, Jan D'hooge, Tom Dresselaers, Uwe Himmelreich, Kenneth D Bloch, Stefan Janssens
Journal: Circulation (2010)
Atlas der Harnsteine. Zugleich eine krystallographisch-chemische Studie über deren Entstehung.
Authors: H. ナカノ, Volker Blüm
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2429: Non-Revascularized Human Hibernating and Chronically Stunned Myocardium Can Adapt to Long-Term Chronic Ischemia
Authors: Henrik Wiggers, Soren Steen Nielsen, Paw Holdgaard, Christian Flo, Helene Norrelund, Mads Halbirk, Torsten Toftegaard Nielsen, Henrik Egeblad, Michael Rehling, Hans Erik Botker
Journal: Circulation (2006)

Background: It is unknown whether human chronically ischemic dysfunctional myocardium degenerates over time or adapts to chronic ischemia through cell survival mechanisms. We studied whether perfus...
Risk-adapted management of stage I seminoma: The second Spanish Germ Cell Cancer Group (GG) study
Authors: J. Aparicio, J. R. Germa, X. Garcia Del Muro, P. Maroto, J. A. Arranz, A. Saenz, A. Barnadas, J. Dorca, E. Alba
Journal: Journal of Clinical Oncology (2004)

4518 Background: Patients with stage I seminoma can be managed with surveillance, prophylactic irradiation or adjuvant chemotherapy. In a previous GG trial (Ann Oncol 2003;14:867) we demonstrated that adjuvant carboplatin may be restricted to patients with risk criteria (RC). The present study was designed to confirm the efficacy of this risk-adapted policy using the new International criteria (JCO 2002;20:4448). Methods: From January 1999 through December 2003, 300 patients (median age 32 years, range 19–66) with stage I seminoma (median tumor size 4.5 cm, range 3–14) were included. 96 (32%) of them had no RC and were managed with surveillance, whereas 125 (42%) had tumors >4 cm, 31 (10%) had rete testis involvement, and 48 (16%) had both RC. The latter 3 groups received single agent adjuvant carboplatin (AUC 7 x 2 cycles with a 21-day interval). Results: Chemotherapy was generally well tolerated, with uncomplicated grade 3–4 myelotoxicity in 7% of patients and grade 1 asthenia in 19%. Median follow-up time is 20 months (range, 1–60). Relapses were observed in 4 (4.2%) patients on surveillance and in 5 (2.4%) treated with adjuvant carboplatin (0.8% of tumors >4 cm, 3.2% of tumors invading rete testis, and 6.3% of tumors with both RC). All relapses were located at retroperitoneum (median size was 18 mm, range 11–35, and median time to relapse was 8 months, range 4–19). All these patients were rendered disease-free with chemotherapy (etoposide + cisplatin). Overall 3-year survival is 100%. Actuarial 3-year event-free survival is 96.4% for patients treated with adjuvant chemotherapy and 94.5% for patients on surveillance. Conclusions: Single-agent carboplatin is effective in reducing the relapse rate in patients with stage I seminoma and RC according to the new International score. A risk-adapted treatment policy is feasible in a national-wide multicenter setting. No significant financial relationships to disclose.
Medieval and Renaissance Medicine.
Authors: Arthur L. Bloomfield
Journal: Annals of Internal Medicine (1960)

hopes that this book 'will fill the gap between Claudius Galen and Thomas Sydenham'.He has achieved his purpose in filling the gap by shovelling in, so to speak, a vast quantity of information gathered from many different sources, some admittedly of uncertain origins.The tracing of any original source is made more difficult first by the fact that this weighty volume has no subject-index, only an index of names; and secondly by the inconvenient plan of collecting together the references for each chapter under the heading of 'Notes' and lumping these all together at the end of the book.One gets the impression that this book has been put together rather hastily.Some- one should have noticed that several identical sentences appear on pages I I2 and 433.Spelling of proper names must always be a difficulty in a book such as this and a certain amount of latitude must be allowed, but there are limits.Admittedly the name ofour greatly esteemed historian Sir D'Arcy Power is likely to present difficulties on the other side of the Atlantic, but he becomes scarcely recognizable as 'D'Arey, Sir.P.' in which disguise he appears on page 798.These are exasperating trifles.The good stuffis there too!For instance, the chapters dealing with Jewish contributions to medicine in the Middle Ages and with Scholas- ticism and Medicine.In fact, this book is really a mine of information but without a subject-index and with such inconveniently placed references the hidden treasure is unnecessarily difficult to find.
Geographic Medicine for the Practitioner.
Authors: Kenneth S. Warren, Adel A. F. Mahmoud
Journal: Annals of Internal Medicine (1979)

1. Prevention of Exotic Diseases: Advice to Travelers.- Viral Infections.- 2. Acute Viral Hepatitis.- 3. Major Tropical Viral Infections: Yellow Fever, Dengue, and Hemorrhagic Fevers (Arena and Ebola).- Bacterial Infections.- 4. Cholera.- 5. Leprosy.- 6. Plague.- 7. Shigellosis.- 8. Tuberculosis.- 9. Typhoid Fever.- Protozoan Infections.- 10. Amebiasis.- 11. Giardiasis.- 12. Leishmaniases.- 13. Malaria.- 14. Toxoplasmosis.- 15. African Trypanosomiases.- 16. American Trypanosomiasis.- Helminth Infections.- 17. Ascariasis and Toxocariasis.- 18. Echinococcosis.- 19. Enterobiasis.- 20. The Filariases.- 21. Flukes: Liver, Intestinal, and Lung.- 22. Hookworm.- 23. Schistosomiasis.- 24. Strongyloidiasis.- 25. Tapeworms.- 26. Trichinosis.- 27. Trichuriasis.
Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM)
Authors: A Devergie, D Blaise, M Attal, JD Tigaud, JP Jouet, JP Vernant, P Bordigoni, N Ifrah, C Dauriac, JY Cahn
Journal: Blood (1995)
Abstract 5445: Gli2 and Gli3 Are Over-expressed in the Ischemic Tissue and Participate in Ischemia-induced Angiogenesis and Myogenesis
Authors: Marie-Ange Renault, Jerome Roncalli, Joern Tongers, Hiromichi Hamada, Tina Thorne, Sol Misener, Aiko Ito, Trevor Clarke, Meredith Millay, Andrew Scarpelli, Ekaterina Klyachko, Douglas W Losordo
Journal: Circulation (2008)

Gli transcription factors are mediators of hedgehog signaling and have been shown to be critical in several steps during development. In addition, Gli transcription factors have also been implicated as potent oncogenes. We have shown that the Hedgehog pathway is reactivated in the adult cardiovascular system under ischemic conditions and that the hedgehog pathway can be exploited therapeutically in ischemic disease; however the role and expression of the Gli transcription factors in the response to injury following ischemia have not been characterized. We induced hind-limb ischemia by resection of the left femoral artery of FVB mice and found that Gli2 and Gli3 mRNA were overexpressed in the ischemic tissue up to 4-fold and 9-fold respectively while Gli1 expression was not modulated. Immunostaining revealed that several cell types overexpressed Gli2 and Gli3 including myocytes and endothelial cells (ECs). To investigate the role and mechanism of action of Gli2 and Gli3, in vitro experiments were first performed. Overexpression of Gli2 and Gli3 promotes myoblast survival and proliferation. In ECs, overexpression of Gli2 and Gli3 promote survival and migration as well as induce expression of proteins involved in angiogenesis such as MMP-9 and osteopontin. To confirm the hypothesis of a favorable role of Gli2 and Gli3 in neovascularization and tissue repair following ischemic injury, adenovirus encoding LacZ, Gli2 and Gli3 were administrated locally in the tibialis anterior muscle, 2 days before hind limb ischemia surgery was performed. Both Ad-Gli2 and Ad-Gli3 treated mice exhibited higher proliferation in the regenerating muscle 7 days after ischemia. Moreover, Ad-Gli3 treated mice display higher capillary density (38.9±10.2 vessels/HPF vs. 26.1±6.1 in the control mice, p=0.012) and limb perfusion (the ratio of the perfusion of the ischemic leg vs. the control leg was 1.07±0.20 vs. 0.62±0,16 for the control mice, p=0.0003) 7 and 14 day after ischemia respectively. These data indicate that Gli2 and Gli3, transcription factors of the hedgehog pathway, are overexpressed in ischemic tissue and participate in tissue repair by promoting both neovascularization and proliferation and survival of myoblasts.
Photosensitivity
Authors: Warwick L. Morison
Journal: New England Journal of Medicine (2004)

A 30-year-old white woman has a 72-hour history of a pruritic rash on her arms and chest. This is the third episode of the rash this summer, and each episode began in the evening after she had spent less than 30 minutes by a swimming pool in the morning. She has no history of sensitivity to sunlight and is taking no medications. Both the rash and the pruritus are improving, but she still has discomfort. How should this woman be evaluated and treated?
Histocompatibility Genes of the Mouse. I. Demonstration of Weak Histocompatibility Differences by Immunization and Controlled Tumor Dosage&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: George D. Snell
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Histocompatibility Genes of the Mouse. I. Demonstration of Weak Histocompatibility Differences by Immunization and Controlled Tumor Dosage Get access George D. Snell George D. Snell Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 4, April 1958, Pages 787–824, https://doi.org/10.1093/jnci/20.4.787 Published: 01 April 1958 Article history Received: 25 October 1957 Published: 01 April 1958
Abstract 3646: A Novel Therapeutic Program of Exercise after Administration of Lipo-PGE1 and Heparin for Patients with Non Option Peripheral Arterial Disease
Authors: Takanori Yasu, Kenshiro Arao, Hiroto Ueba, Nahoko Ikeda, Nobuhiko Kobayashi, Norifumi Kubo, Masanobu Kawakami, Muneyasu Saito, Shin-ichi Momomura
Journal: Circulation (2006)

BACKGROUND: A program combining heparin administration with exercise is a useful therapeutic strategy for stimulation of collateral development in ischemic legs in patients with non-option peripheral arterial disease (PAD) via transient increase in hepatocyte growth factor. The aim was to examine a hypothesis that additional combination of lipo-prostaglandin (PG) E1, a potent vasodilator and inhibitor of platelet aggregation, accelerates the effectiveness of heparin + exercise program in patients with non-option PAD.

METHODS: Study patients were 20 symptomatic PAD (Fontaine II or III) patients who were not candidates for surgical or nonsurgical revascularization because of the lack of distal target vessels or other reasons such as high surgical risk. The patients were randomly assigned in a double blind fashion to two groups; a group of lipo-PGE1(+) (supervised walking for 60 min/day after intravenous administration of 3,000 units heparin and 10 μg lipo-PGE1 for 14 days, n=10) and a group of lipo-PGE1(−) (same supervised walking program after administration of heparin and saline, n=10). After 14-day-initial treatment, the patients of both groups did ambulatory exercise under supervision for 60 min once a day, 3 days/week during a period of following 22 weeks. Ankle brachial pressure index (ABI) and Treadmill test (2.5 km/h, 12% slope) were done before, 2 weeks, 12 weeks, and 24 weeks after the start of program. Ophthalmic examinations and digital subtraction angiography of lower extremities were repeated before and at 24 weeks.

RESULTS: Maximum walking time in Treadmill test significantly increased in the group of lipo-PGE1(+) compared with the group of lipo-PGE1(−) at 2 weeks (7.0 ± 2.4 min, 4.8 ± 1.8 min, respectively, P<0.05) but not at 12 weeks (9.2 ± 3.2 min, 7.4 ± 3.1 min, ns) or 24 weeks(10.1 ± 3.6 min, 7.9 ± 3.2 min, ns). There was no significant difference in ABI between two groups through the study period. There were no patients who showed pathological retinal angiogenesis at 24 weeks.

CONCLUSION: 

Additional administration of lipo-PGE1 on heparin + exercise program brings the therapeutic gain appearance forward. This beneficial short-term effect may encourage patients with non-option PAD to maintain exercise training.
Endocrinology of Reproduction
Authors: Joseph Thomas Velardo
Journal: BMJ (1945)

In attempting to present a relatively clear and useful summary of the available information and existing problems in the field of reproduction, the authors have succeeded remarkably well, despite the admitted complexity of the subject matter and the fact that research involving some aspects has been extremely fruitful during the past few decades. Among the topics covered in separate chapters are the genetics of reproduction, embryology of the reproductive system, pituitary and hypothalamus, mammary gland development and function, and the dynamics of endocrinology. The editor and authors have spent much time and effort in providing numerous references to support their conclusions and to provide source material for those who are interested in exploring certain problems in further detail. The material is well integrated and chapter delineation is good, despite inherent difficulties in achieving this when various authors contribute on similar subjects. One instance of divergent views relates to the number
Fluoroquinolone resistance
Authors: L. J V Piddock
Journal: BMJ (1998)

<h3>Background</h3> The UK has been one of the European countries most affected by COVID-19 pandemic. The UK implemented a lockdown in March 2020, when testing policy at the time was focusing on hospitalised cases. Limited information is therefore available on the impact of the lockdown on point prevalence in the community. We assessed COVID-19 point prevalence in London between early April and early May 2020, which approximately reflect infection around the time of the lockdown and 3–5&nbsp;weeks into lockdown. <h3>Methods</h3> We tested 1064 participants of a community surveillance cohort for acute COVID-19 infection using PCR in London in April and May 2020 and described positivity as well as characteristics and symptoms of the participants. <h3>Results</h3> Point prevalence decreased from 2.2% (95% CI 1.4 to 3.5) in early April to 0.2% (95% CI 0.03 to 1.6) in early May. 22% of those who tested positive in April were asymptomatic. Extrapolation from reports of confirmed cases suggest that 5–7.6% of total infections were confirmed by testing during this period. <h3>Conclusion</h3> COVID-19 point prevalence in the community sharply decreased after lockdown was implemented. This study is based on a small sample and regular seroprevalence studies are needed to better characterise population-level immunity.
Web-based stepped collaborative care intervention in the context of advanced cancer.
Authors: Jennifer Lynne Steel, Kevin H Kim, Lisa Butterfield, Michael Spring, Jonathan Grady, Deborah Brower, J. Wallis Marsh, Weijing Sun, Mary Amanda Dew, Michael Antoni, Allan Tsung
Journal: Journal of Clinical Oncology (2014)

9522 Background: According to the NIH consensus statement, the three most common and debilitating symptoms for cancer patients are depression, pain and fatigue. The aims of this study were to test the efficacy of a web-based collaborative care intervention to reduce cancer-related symptoms and improve quality of life in advanced cancer patients. Methods: Patients with advanced cancer were randomized to a web-based stepped collaborative care intervention or usual care arm. The primary outcomes of the intervention included the Center for Epidemiological Studies-Depression (CES-D), Brief Pain Inventory, the Functional Assessment of Cancer Therapy (FACT)-Fatigue, and the FACT-Hepatobiliary. Secondary outcomes included Interleukin (IL)-1b, IL-6 and Natural Killer cells and the Caregiver Quality of Life Index and Caregiver CES-D. An intent to treat analyses was performed and effect sizes were reported using the Cohen’s d (Small<0.20; Medium=0.30-0.70; Large>0.80) or Phi (Small=0.10; Medium=0.30; Large=0.50). Results: A total of 261 patients and 179 caregivers were enrolled in the study. Patients with clinical levels of symptoms, who were randomized to the intervention arm, reported reductions in depression (Cohen’s d=0.32), pain (Cohen’s d=0.74), fatigue (Cohen’s d=0.48) and improvements in quality of life (Cohen’s d =0.38) when compared to patients randomized to the usual care arm at 6-months. Patients randomized to the intervention arm also had reductions in IL-6 (Phi=0.34), IL-1b (Phi=0.38) and increases in NK cell numbers (Phi=0.49). The family caregivers of patients randomized to the intervention arm also had lower levels of stress (Cohen’s d=0.75) and depressive symptoms (Cohen’s d=0.37) when compared to the usual care arm at 6-months. Conclusions: The web-based collaborative care intervention was found to be effective in reducing cancer-related symptoms, immune system dysregulation, and improving quality of life in both the patients and family caregivers. Clinical trial information: NCT01640522.